» Articles » PMID: 21975863

Resveratrol Improves Renal Microcirculation, Protects the Tubular Epithelium, and Prolongs Survival in a Mouse Model of Sepsis-induced Acute Kidney Injury

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2011 Oct 7
PMID 21975863
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

The mortality rate of patients who develop acute kidney injury during sepsis nearly doubles. The effectiveness of therapy is hampered because it is usually initiated only after the onset of symptoms. As renal microvascular failure during sepsis is correlated with the generation of reactive nitrogen species, the therapeutic potential of resveratrol, a polyphenol vasodilator that is also capable of scavenging reactive nitrogen species, was investigated using the cecal ligation and puncture (CLP) murine model of sepsis-induced acute kidney injury. Resveratrol when given at 5.5 h following CLP reversed the decline in cortical capillary perfusion, assessed by intravital microscopy, at 6 h in a dose-dependent manner. Resveratrol produced the greatest improvement in capillary perfusion and increased renal blood flow and the glomerular filtration rate without raising systemic pressure. A single dose at 6 h after CLP was unable to improve renal microcirculation assessed at 18 h; however, a second dose at 12 h significantly improved microcirculation and decreased the levels of reactive nitrogen species in tubules, while improving renal function. Moreover, resveratrol given at 6, 12, and 18 h significantly improved survival. Hence, resveratrol may have a dual mechanism of action to restore the renal microcirculation and scavenge reactive nitrogen species, thus protecting the tubular epithelium even when administered after the onset of sepsis.

Citing Articles

Sepsis-Associated Acute Kidney Injury: Pathophysiology and Treatment Modalities.

Aguilar M, AlHussen H, Gandhi P, Kaur P, Pothacamuri M, Talikoti M Cureus. 2025; 16(12):e75992.

PMID: 39834999 PMC: 11743060. DOI: 10.7759/cureus.75992.


Evaluation of the protective role of resveratrol on LPS-induced septic intestinal barrier function via TLR4/MyD88/NF-κB signaling pathways.

Shi Z, Jiao Y, Lai Z, Liu J, Yang B, Hu M Sci Rep. 2025; 15(1):828.

PMID: 39755761 PMC: 11700184. DOI: 10.1038/s41598-025-85148-2.


COVID-19-Associated Sepsis: Potential Role of Phytochemicals as Functional Foods and Nutraceuticals.

De Souza Goncalves B, Sangani D, Nayyar A, Puri R, Irtiza M, Nayyar A Int J Mol Sci. 2024; 25(15).

PMID: 39126050 PMC: 11312872. DOI: 10.3390/ijms25158481.


Focus on Mitochondrial Respiratory Chain: Potential Therapeutic Target for Chronic Renal Failure.

Wang Y, Yang J, Zhang Y, Zhou J Int J Mol Sci. 2024; 25(2).

PMID: 38256023 PMC: 10815764. DOI: 10.3390/ijms25020949.


Molecular Mechanisms of Oxidative Stress in Acute Kidney Injury: Targeting the Loci by Resveratrol.

Rashid H, Jali A, Akhter M, Abdi S Int J Mol Sci. 2024; 25(1).

PMID: 38203174 PMC: 10779152. DOI: 10.3390/ijms25010003.


References
1.
Holthoff J, Woodling K, Doerge D, Burns S, Hinson J, Mayeux P . Resveratrol, a dietary polyphenolic phytoalexin, is a functional scavenger of peroxynitrite. Biochem Pharmacol. 2010; 80(8):1260-5. PMC: 2934873. DOI: 10.1016/j.bcp.2010.06.027. View

2.
Brandt S, Regueira T, Bracht H, Porta F, Djafarzadeh S, Takala J . Effect of fluid resuscitation on mortality and organ function in experimental sepsis models. Crit Care. 2009; 13(6):R186. PMC: 2811934. DOI: 10.1186/cc8179. View

3.
Nguyen H, Corbett S, Menes K, Cho T, Daugharthy J, Klein W . Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department. Acad Emerg Med. 2005; 13(1):109-13. DOI: 10.1197/j.aem.2005.08.005. View

4.
Baur J, Sinclair D . Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006; 5(6):493-506. DOI: 10.1038/nrd2060. View

5.
Russell J . Management of sepsis. N Engl J Med. 2006; 355(16):1699-713. DOI: 10.1056/NEJMra043632. View